EDAP Edap Tms S.A. ADS

EDAP TMS SA to Announce Fourth Quarter and Full Year 2020 Financial Results on March 30, 2021

EDAP TMS SA to Announce Fourth Quarter and Full Year 2020 Financial Results on March 30, 2021

Company to host conference call and webcast on Wednesday, March 31 at 8:30 am EDT

LYON, France, March 23, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2020 after the markets close on Tuesday, March 30, 2021.

An accompanying conference call and webcast will be conducted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Wednesday, March 31, 2021. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast

Wednesday, March 31st @ 8:30am Eastern Time

Domestic:                    877-451-6152

International:              201-389-0879

Passcode:                    13717550

Webcast:                    

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.  EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit , and .

Company Contact

Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

50

Investor Contact

Jeremy Feffer

LifeSci Advisors, LLC

212-915-2568

 



EN
23/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Edap Tms S.A. ADS

 PRESS RELEASE

EDAP Announces Appointment of David Horn to Board of Directors

EDAP Announces Appointment of David Horn to Board of Directors          EDAP Announces Appointment of David Horn to Board of Directors AUSTIN, Texas, February 12, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) (“the Company” or “EDAP”), a global leader in therapeutic ultrasound technology, today announced the appointment of David Horn to its Board of Directors, effective February 11, 2026. The addition of Mr. Horn strengthens the Board with extensive experience both advising and leading companies through periods of strategic growth and transformation. Mr. Horn will serve as a member of the Company’...

 PRESS RELEASE

EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HI...

EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue Guidance EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue Guidance 36% to 38% Annual YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in Number of U.S. Focal One Procedures 69% Annual YoY Growth in Focal One System Placements 28% Q4 YoY Growth in U.S. Procedures Highlights Accelerating Quarterly Procedure Growth AUSTIN, Texas, January 12, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (“the Compan...

 PRESS RELEASE

EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One R...

EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU  EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU  AUSTIN, Texas, November 20, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for new ultrasound imaging and workflow enhancements to the Focal One High Intensity Focused Ultrasound (HIFU) system, further strengthening the company’s market leadership in robotic focal therapy for prostate cancer. ...

 PRESS RELEASE

EDAP to Present at Piper Sandler 37th Annual Healthcare Conference

EDAP to Present at Piper Sandler 37th Annual Healthcare Conference EDAP to Present at Piper Sandler 37th Annual Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Tuesday, December 2nd, 2025 AUSTIN, Texas, November 18, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Chief Executive Officer Ryan Rhodes is scheduled to present and, together with Chief Financial Officer Ken Mobeck, will host 1x1 investor meetings at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York Cit...

 PRESS RELEASE

EDAP Reports Third Quarter 2025 Financial Results

EDAP Reports Third Quarter 2025 Financial Results EDAP Reports Third Quarter 2025 Financial Results 49% YoY HIFU Revenue Growth, Driven by Increased Focal One® Sales and U.S. Procedure Volumes167% YoY Growth in Focal One System Placements15% YoY Growth in U.S. Focal One HIFU ProceduresCompany to Host Conference Call and Webcast on November 6 at 8:30 a.m. ET AUSTIN, Texas, November 6, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the third quarter of 2025. “Our record-breaking third-quart...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch